| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $6.5M | +27.5% | +105.2% |
| SG&A Expense | $3.6M | -11.7% | +1.9% |
| Operating Income | -$10.2M | -10.0% | -224.6% |
| Interest Expense | $0 | — | -100.0% |
| Pre-tax Income | -$11.3M | -19.8% | -67.5% |
| Income Tax | $0 | — | — |
| Net Income | -$11.3M |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $63.6M | -9.7% | +228.3% |
| Accounts Receivable | $0 | — | -100.0% |
| Current Assets | $66.9M | -9.2% | — |
| Total Assets | $66.9M | -9.2% | +226.2% |
| Current Liabilities | $10.3M | +7.2% | +142.4% |
| Total Liabilities | $28.3M |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$20.1M | — | — |
| Financing Cash Flow | -$611K | — | — |
| -293.0% |
| EPS (Basic) | -$1.03 | -19.8% | +53.0% |
| EPS (Diluted) | -$1.03 | -19.8% | +53.0% |
| +8.8% |
| — |
| Stockholders' Equity | $38.7M | -19.0% | +137.8% |